Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-91278

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP1-91278
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Sample Type & Volume Required Per Well

Cell culture supernatant, serum (50 uL)

Sensitivity

0.2 ng/mL

Assay Range

0.78 - 50 ng/mL

View all 4-1BB/TNFRSF9/CD137 ELISA Kits »

Product Specifications

Assay Type

Sandwich ELISA

Kit Type

ELISA Kit (Colorimetric)

Reactivity

Human

Specificity

The interference of circulating factors of the immune systemwas evaluated by spiking these proteins at physiologically relevant concentrations into a human 4-1BB/TNFRSF9/CD137 positive serum. There was no crossreactivity detected.

Description

The human sCD137 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human sCD137.

Precision

Intra-Assay Precision (Precision within an assay) CV% < 7.10%

Inter-Assay Precision (Precision between assays) CV% < 9.90%

Recovery for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

Recovery

90%

Scientific Data Images for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

4-1BB/TNFRSF9/CD137 ELISA Kit [NBP1-91278] - Data for Human sCD137 (s4-1BB) Platinum ELISA

Kit Contents for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

  • Adhesive Films
  • Aluminium pouch(es) with a Microwell Plate coated with monoclonal antibody to human sCD137
  • Assay Buffer Concentrate 20x (PBS with 1% Tween 20 and 10% BSA)
  • Biotin-Conjugate anti-human sCD137 polyclonal antibody
  • Human sCD137 Standard lyophilized, 100 ng/ml upon reconstitution
  • Sample Diluent
  • Stop Solution (1M Phosphoric acid)
  • Streptavidin-HRP
  • Substrate Solution (tetramethyl-benzidine)
  • Wash Buffer Concentrate 20x (PBS with 1% Tween 20)

Preparation and Storage

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Storage of components varies. See protocol for specific instructions.

Background: 4-1BB/TNFRSF9/CD137

4-1BB, also called CD137 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9), is a type I surface glycoprotein expressed on activated T cell and natural killer (NK) cells (1,2). Human 4-1BB protein is 255 amino acids (aa) in length with a theoretical molecular weight of 28 kDa. It contains an extracellular domain, a helical transmembrane domain, and a cytoplasmic/intracellular domain (3). 4-1BB/TNFRSF9/CD137 is a costimulatory receptor that binds the ligand 4-1BBL/CD137L which is primarily expressed on antigen presenting cells (APCs) such as dendritic cells (DCs), macrophages, and B cells (1,2,4,5). The 4-1BB receptor-ligand interaction results in recruitment of TNFR-associated factor (TRAF) family adaptor proteins to 4-1BB's cytoplasmic domain (1,2,4,5). TRAF1, TRAF2, and TRAF3 are found in various homodimer and/or heterodimer configurations. Their recruitment to 4-1BB/CD137 initiates signalosome formation as well as activation of the nuclear factor-kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling cascade (1,4,5). 4-1BB/TNFRSF9/CD137 stimulation leads to increased cellular cytotoxic activity and pro-inflammatory cytokine production (1,2,4). Given its role in immune cell activation, 4-1BB has become a promising target for cancer immunotherapy (1,2,4). Current approaches to target 4-1BB include agonistic monoclonal and bispecific anti-4-1BB antibodies and well as utilizing the cytoplasmic domain of 4-1BB in generating chimeric antigen receptors (CARs) (1,2,4). 4-1BB agonists in clinical trials include Urelumab and Utolimumab. Utolimumab also has ligand blocking properties whereas Urelumab does not (1,2,4). Anti-4-1BB monoclonal antibodies are being tested as monotherapy as well as combination therapy with either other immunostimulatory monoclonal antibodies or with checkpoint blockade antibodies like anti-PD-1 (1,2,4).

References

1. Etxeberria, I., Glez-Vaz, J., Teijeira, A., & Melero, I. (2020). New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO open, 4(Suppl 3), e000733. https://doi.org/10.1136/esmoopen-2020-000733

2. Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018). Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 131(1), 49-57. https://doi.org/10.1182/blood-2017-06-741041

3. Uniport (Q07011)

4. Chester, C., Ambulkar, S., & Kohrt, H. E. (2016). 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunology, Immunotherapy: CII, 65(10), 1243-1248. https://doi.org/10.1007/s00262-016-1829-2

5. Zapata, J. M., Perez-Chacon, G., Carr-Baena, P., Martinez-Forero, I., Azpilikueta, A., Otano, I., & Melero, I. (2018). CD137 (4-1BB) signalosome: complexity is a matter of TRAFs. Frontiers in Immunology, 9, 2618. https://doi.org/10.3389/fimmu.2018.02618

Alternate Names

41BB, CD137, ILA, TNFRSF9

Gene Symbol

TNFRSF9

Additional 4-1BB/TNFRSF9/CD137 Products

Product Documents for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.